CA2437215A1 - Composes de dihydropyrazolopyridine et leur utilisation pharmaceutique - Google Patents

Composes de dihydropyrazolopyridine et leur utilisation pharmaceutique Download PDF

Info

Publication number
CA2437215A1
CA2437215A1 CA002437215A CA2437215A CA2437215A1 CA 2437215 A1 CA2437215 A1 CA 2437215A1 CA 002437215 A CA002437215 A CA 002437215A CA 2437215 A CA2437215 A CA 2437215A CA 2437215 A1 CA2437215 A1 CA 2437215A1
Authority
CA
Canada
Prior art keywords
dihydro
pyridine
pyrazolo
ethyl
carboxylate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002437215A
Other languages
English (en)
Inventor
Toshiyuki Kohara
Kenji Fukunaga
Masatake Fujimura
Tokushi Hanano
Hirotaka Okabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Pharma Corp
Original Assignee
Mitsubishi Pharma Corporation
Toshiyuki Kohara
Kenji Fukunaga
Masatake Fujimura
Tokushi Hanano
Hirotaka Okabe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corporation, Toshiyuki Kohara, Kenji Fukunaga, Masatake Fujimura, Tokushi Hanano, Hirotaka Okabe filed Critical Mitsubishi Pharma Corporation
Publication of CA2437215A1 publication Critical patent/CA2437215A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002437215A 2001-02-02 2002-02-01 Composes de dihydropyrazolopyridine et leur utilisation pharmaceutique Abandoned CA2437215A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2001-26379 2001-02-02
JP2001026379 2001-02-02
JP2001081238 2001-03-21
JP2001-81238 2001-03-21
JP2001-304707 2001-09-28
JP2001304707 2001-09-28
PCT/JP2002/000829 WO2002062795A2 (fr) 2001-02-02 2002-02-01 Composes de dihydropyrazolopyridine et leur utilisation pharmaceutique

Publications (1)

Publication Number Publication Date
CA2437215A1 true CA2437215A1 (fr) 2002-08-15

Family

ID=27345889

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002437215A Abandoned CA2437215A1 (fr) 2001-02-02 2002-02-01 Composes de dihydropyrazolopyridine et leur utilisation pharmaceutique

Country Status (6)

Country Link
EP (1) EP1355909A2 (fr)
JP (1) JP2005501800A (fr)
KR (1) KR20030076650A (fr)
CN (1) CN1630656A (fr)
CA (1) CA2437215A1 (fr)
WO (1) WO2002062795A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003250539A1 (en) * 2002-08-07 2004-02-25 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds
WO2004037814A1 (fr) * 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Compositions indazolinones utiles en tant qu'inhibiteurs des kinases
ES2214150B1 (es) * 2003-02-27 2005-12-01 J. URIACH & CIA S.A. "nuevos derivados de pirazolopiridinas".
ATE481402T1 (de) * 2003-02-27 2010-10-15 Palau Pharma Sa Pyrazolopyridin-derivate
EP1663220B1 (fr) * 2003-09-03 2009-12-02 Glaxo Group Limited Nouveau procede pour la fabrication de derives de la pleuromutiline
WO2005099688A2 (fr) 2004-04-07 2005-10-27 Takeda Pharmaceutical Company Limited Composes cycliques
RS51351B (en) 2005-07-20 2011-02-28 Aventis Pharma S.A. 1,4-DIHYDROPYRIDINE-CONDENSED HTEROCYCLES, PROCEDURES FOR THEIR PRODUCTION, USE AND THE COMPOSITIONS CONTAINING THEM
EP2291187B1 (fr) 2008-04-24 2018-08-15 Newlink Genetics Corporation Inhibiteurs des ido
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant
US9096594B2 (en) 2012-10-12 2015-08-04 The Broad Institute, Inc. Kinase inhibitors and methods of use thereof
WO2018187630A1 (fr) 2017-04-05 2018-10-11 The Broad Institute, Inc. Composés tricycliques en tant qu'inhibiteurs de glycogène synthase kinase 3 (gsk3) et leurs utilisations
AU2020218366A1 (en) 2019-02-08 2021-09-16 Frequency Therapeutics, Inc. Valproic acid compounds and Wnt agonists for treating ear disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3790576A (en) * 1972-03-20 1974-02-05 Parke Davis & Co 9 substituted 4,9-dihydro-1,3,4,4-tetraalkyl-1h-pyrazolo(3,4-b)quinolines
JPS5965089A (ja) * 1982-10-05 1984-04-13 Shionogi & Co Ltd ジヒドロピラゾロ〔３，４−ｂ〕ピリジン誘導体およびその製造法
JPS60197685A (ja) * 1984-03-19 1985-10-07 Shionogi & Co Ltd ４，７―ジヒドロピラゾロ［３，４―ｂ］ピリジン誘導体とその製造法
GR79111B (fr) * 1982-12-20 1984-10-02 Lepetit Spa
JPS6056979A (ja) * 1983-09-08 1985-04-02 Shionogi & Co Ltd ４，７−ジヒドロピラゾロ〔３，４−ｂ〕ピリジン誘導体およびその製造法
US4822799A (en) * 1988-01-27 1989-04-18 Sandoz Pharm. Corp. Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
EP0355234A1 (fr) * 1988-08-25 1990-02-28 Merrell Dow Pharmaceuticals Inc. Dérivés de la pyrazolo-pyridine avec activité antiethérosclérotique et hypecholesthérolémique
WO1992003137A1 (fr) * 1990-08-23 1992-03-05 The Children's Medical Center Corporation Traitement des demences, des myelopathies, des neuropathies peripheriques et des pertes de vision liees au sida
US6489344B1 (en) * 1998-06-19 2002-12-03 Chiron Corporation Inhibitors of glycogen synthase kinase 3
JP2003525939A (ja) * 2000-03-03 2003-09-02 アボット・ラボラトリーズ 三環式ジヒドロピラゾロン及び三環式ジヒドロイソオキサゾロンカリウムチャンネル開放剤
WO2001081345A1 (fr) * 2000-04-20 2001-11-01 Mitsubishi Pharma Corporation Composes d'amides aromatiques

Also Published As

Publication number Publication date
EP1355909A2 (fr) 2003-10-29
WO2002062795A3 (fr) 2003-05-30
KR20030076650A (ko) 2003-09-26
JP2005501800A (ja) 2005-01-20
CN1630656A (zh) 2005-06-22
WO2002062795A9 (fr) 2002-10-10
WO2002062795A2 (fr) 2002-08-15

Similar Documents

Publication Publication Date Title
DE60129210T2 (de) Zyklische amid-derivate
JP2793195B2 (ja) ベンゾチアゾール誘導体
EP0804437B1 (fr) DERIVES DE PYRROLE a]-ANNELES ET LEUR UTILISATION DANS LE DOMAINE PHARMACEUTIQUE
JP2008543726A (ja) 炎症性疾患の処置のためのｐｇｄ２受容体アンタゴニスト
WO2001081345A1 (fr) Composes d'amides aromatiques
JPH061788A (ja) 新規なアザインドール、その製造方法及びそれらを含む医薬品
AU7444898A (en) A new process for the preparation of a pharmacologically active substance
FR2959510A1 (fr) Derives de pyrido[3,2-d]pyrimidine, leurs procedes de preparation et leurs utilisations therapeutiques
RU2154635C2 (ru) Производные 4-арил-6-амино-никотиновой кислоты и их соли
TW401299B (en) Use of 5-substituted pyridine-and hexahydroquinoline-3-carboxylic acid derivatives for the treatment of disorders of the central nervous system, novel active compounds, a process for their preparation and their use
CA1294967C (fr) Derives du 1h, 3h-pyrrolo [1,2-c] thiazole, leur preparation et les compositions pharmaceutiques qui les contiennent
CA2437215A1 (fr) Composes de dihydropyrazolopyridine et leur utilisation pharmaceutique
CZ657890A3 (cs) Chromanový derivát, způsob jeho výroby a farmaceutický prostředek s jeho obsahem
US6977262B2 (en) Dihydropyrazolopyridine compounds and pharmaceutical use thereof
AU2018352828A1 (en) Antagonists of the muscarinic acetylcholine receptor M4
KR20180049056A (ko) 삼환식 축합피리딘-2－온 유도체 및 이들의 brd4 저해제로서의 용도
WO2016148114A1 (fr) Composé capable d'inhiber une mort de cellule neuronale induite par stress oxydatif
EP2880023A1 (fr) Derives de griseofulvine
IL144229A (en) New history of N) –2– cyanoimino) thiazolidine – 4 – on
WO1986001510A1 (fr) Agents anti-inflammatoires a l'oxindole tricyclique
JP2959598B2 (ja) 光学活性なチエノトリアゾロジアゼピン化合物
JP2019536759A (ja) 置換された二環式ヘテロアリール系ニコチン性アセチルコリン受容体アロステリック調節剤
NO317296B1 (no) Hypnotisk <beta>- karbolinderivater, fremgangsmater til deres fremstilling og deres anvendelse som legemiddelprodukt
JP5419894B2 (ja) Ｔｒｐｖ３モジュレーターとしての縮合ピリミジン誘導体
WO2001014384A1 (fr) Derives dihydrobenzofuran tricycliques, leur procede de preparation et agents

Legal Events

Date Code Title Description
FZDE Dead